Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.
ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma